Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma

Australasian Radiology

Volumn 42, Issue 2, 1998, Pages 157-158

  Jagavkar, R S ^a   Shakespeare, T P ^a   Stevens, M J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Adenosarcoma; Endometrium; Tamoxifen

Indexed keywords

TAMOXIFEN;

AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTEROSCOPY; PRIORITY JOURNAL; VAGINA BLEEDING;

EID: 0031982257     PISSN: 00048461     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1673.1998.tb00596.x     Document Type: Article

References (6)

1. Fornander T, Rutqvist LE, Glas V et al. Adjuvant Tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989; 1: 117-20.
2. Killackey MA, HakesTB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rev. 1985; 69: 237-8.
3. Fisher B, Constantino JP, Redmond CK et al. Endometrial cancer in Tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst. 1994; 86: 527-37.
4. Robinson DC, Bloss JD, Schiano MA. A retrospective study of Tamoxifen and endometrial cancer in breast cancer patients. Gynecol. Oncol. 1995; 59: 186-90.
5. Nephew KP, Polek TC, Khan SA. Tamoxifen-induced protooncogene expression persists in uterine endometrial epithelium. Endocrinology 1996; 137: 219-24.
6. Hardell L. Tamoxifen as a risk factor for adenocarinoma of corpus uteri. Lancet 1988; 2: 563.